All articles by Randy Vogenberg

Randy Vogenberg

Navigating post-approval research and reimbursement for orphan therapies

In the first of this series, we discussed how innovators can be more strategic and effective about reimbursement and address…
How commercial employer plans and coverage matter for orphan drugs

For many years, the market for orphan drugs has reflected an unwritten agreement that small patient numbers could allow public…